KLRK1 as a prognostic biomarker for lung adenocarcinoma cancer

被引:0
|
作者
Yanan Zhang
Zeyang Chen
Aifang Jiang
Guanqi Gao
机构
[1] Weifang Medical University,Clinical Medical College
[2] Linyi People’s Hospital,Clinical Medical College
[3] Qingdao University,undefined
[4] Weifang Medical University,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Lung cancer is one of the most common malignancy worldwide and causes estimated 1.6 million deaths each year. Cancer immunosurveillance has been found to play an important role in lung cancer and may be related with its prognosis. KLRK1, encoding NKG2D, is a homodimeric lectin-like receptor. However, there has not been one research of KLRK1 as a biomarker in lung cancer. Data including patients` clinical characteristics and RNAseq information of KLRK1 from TCGA were downloaded. A total of 1019 patients with lung cancer were included in this study, among which 407 patients were female and 611 patients were male. Evaluations of mRNA expression, diagnostic value by ROC (receiver operating characteristic) curves and prognostic value by survival curve, Cox model and subgroup analysis were performed. The level of KLRK1 expression in lung adenocarcinoma cancer tissues and normal lung tissues was detected by qRT-PCR. The CCK-8 assay investigated the proliferation rate and the wound healing assay assessed the migratory ability in vitro. The expression of KLRK1 in tumor was lower than that in normal tissue. KLRK1 expression was associated with gender, histologic grade, stage, T classification and vital status. Patients with high KLRK1 expression presented an improved overall survival (P = 0.0036) and relapse free survival (P = 0.0031). KLRK1 was found to have significant prognostic value in lung adenocarcinoma (P = 0.015), stage I/II (P = 0.03), older patients (P = 0.0052), and male (P = 0.0047) by subgroup overall survival analysis, and in lung adenocarcinoma (P = 0.0094), stage I/II (P = 0.0076), older patients (P = 0.0072), and male (P = 0.0033) by subgroup relapse free survival analysis. Lung adenocarcinoma cancer patients with high KLRK1 expression presented an improved overall survival (P = 0.015) and relapse free survival (P = 0.0094). In vitro studies indicated that KLRK1 inhibited tumor cell proliferation and migration. KLRK1 was an independent prognostic factor and high KLRK1 expression indicated a better overall and relapse free survival. KLRK1 may be a prognostic biomarker for lung adenocarcinoma cancer.
引用
收藏
相关论文
共 50 条
  • [21] lncRNA VIM-AS1 acts as a prognostic biomarker and promotes apoptosis in lung adenocarcinoma
    Kang, Jianhong
    Abudurufu, Maimaiti
    Zhang, Shuwei
    Jiang, Wei
    Luo, Honghe
    JOURNAL OF CANCER, 2023, 14 (08): : 1417 - 1426
  • [22] TCN1 is a potential prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma
    Haining Li
    Liping Guo
    Zhigang Cai
    World Journal of Surgical Oncology, 20
  • [23] PCM1: A Potential Prognostic Biomarker Correlated with Immune Infiltration in Lung Adenocarcinoma
    Guo, Zhihua
    Liang, Jinghao
    Zhang, Xin
    Ai, Qing
    Xie, Zixian
    Zhao, Haonan
    Wu, Fayuan
    Tan, Zhaofeng
    Yin, Weiqiang
    Ji, Linghua
    CURRENT PROTEOMICS, 2023, 20 (03) : 208 - 221
  • [24] TCN1 is a potential prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma
    Li, Haining
    Guo, Liping
    Cai, Zhigang
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2022, 20 (01)
  • [25] DDX59-AS1: A Novel Prognostic Biomarker and Immunotherapy Predictor in Lung Adenocarcinoma
    Wang, Yanli
    Li, Wei
    Wei, Su
    Zhang, Lixi
    Li, Dongbing
    Qi, Xu
    CURRENT MEDICINAL CHEMISTRY, 2025,
  • [26] P4HA1, a Prognostic Biomarker that Correlates With Immune Infiltrates in Lung Adenocarcinoma and Pan-Cancer
    Zhao, Qi
    Liu, Junfeng
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [27] GPI Is a Prognostic Biomarker and Correlates With Immune Infiltrates in Lung Adenocarcinoma
    Han, Jiahui
    Deng, Xinzhou
    Sun, Renhuang
    Luo, Ming
    Liang, Meng
    Gu, Bing
    Zhang, Te
    Peng, Zhen
    Lu, Ying
    Tian, Chao
    Yan, Yutao
    Luo, Zhiguo
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [28] AL365181.3 as a novel prognostic biomarker for lung adenocarcinoma
    Liu, Xiaoying
    Liu, Jinlong
    Zeng, Yingou
    Qiao, Di
    Wang, Qiang
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [29] Spondin2 is a new prognostic biomarker for lung adenocarcinoma
    Yuan, Xiaopeng
    Bian, Tingting
    Liu, Jian
    Ke, Honggang
    Feng, Jia
    Zhang, Qing
    Qian, Li
    Li, Xiaoli
    Liu, Yifei
    Zhang, Jianguo
    ONCOTARGET, 2017, 8 (35) : 59324 - 59332
  • [30] CBX7, a Potential Prognostic Biomarker in Lung Adenocarcinoma
    Yang, Yanlong
    Hu, Zaoxiu
    Sun, Hongwen
    Yu, Qinghe
    Yang, Linzhu
    Yin, Fang
    Sun, Yongmen
    Pu, Lisha
    Zhu, Xingming
    Li, Sheng
    Chen, Xiaobo
    Zhao, Yunping
    ONCOTARGETS AND THERAPY, 2021, 14 : 5477 - 5492